Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4′-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands
作者:Yi Zheng、Samuel Obeng、Huiqun Wang、Abdulmajeed M. Jali、Bharath Peddibhotla、Dwight A. Williams、Chuanchun Zou、David L. Stevens、William L. Dewey、Hamid I. Akbarali、Dana E. Selley、Yan Zhang
DOI:10.1021/acs.jmedchem.8b01158
日期:2019.1.24
MOR antagonist that may be used to treat OIC. To further explore its structure–activity relationship, a new series of NAP derivatives were designed, synthesized, and biologically evaluated. Among these derivatives, NFP and NYP significantly antagonized the antinociception effect of morphine. Whereas NAP acted mainly peripherally, its derivatives NFP and NYP actually can act centrally. Furthermore, NFP
μ阿片受体(MOR)激动剂已广泛应用于治疗中度至重度疼痛。但是,其应用已引起许多不良反应,包括阿片类药物引起的便秘(OIC),呼吸抑制和成瘾。根据我们实验室NAP先前的工作,一个6β- N-4'-吡啶基取代的纳曲胺衍生物被鉴定为可用于治疗OIC的外周MOR拮抗剂。为了进一步探索其结构-活性关系,设计,合成了一系列新的NAP衍生物,并对其进行了生物学评估。在这些衍生物中,NFP和NYP显着拮抗吗啡的抗伤害感受作用。NAP主要在外围起作用,而其衍生产品NFP和NYP实际上可以在中心起作用。此外,在相似剂量下,NFP产生的戒断症状明显少于纳洛酮。这些结果表明,NFP有潜力成为治疗阿片类药物滥用和成瘾的先导化合物。